Heart failure: a growing public health problem
- PMID: 7852915
- DOI: 10.1111/j.1365-2796.1995.tb01153.x
Heart failure: a growing public health problem
Abstract
At a time when deaths from coronary heart disease and stroke are markedly declining, mortality from heart failure is increasing. Heart failure is a costly and devastating disease, and throughout much of the industrialized world, escalating health-care costs constitute a serious burden on both public and private systems of financing health care, and about one-third of all heart failure patients are admitted to hospital each year. Both prevalance and incidence of heart failure increase steeply with increasing age. The prevalence rate is about 1% at the age of 50, whilst at the age of 80 and above, almost one out of 10 persons will suffer from heart failure. Until recently, the goals for heart failure treatment were to relieve symptoms and enhance functional capacity. Recently, some large scale studies have shown that ACE inhibitors can reduce mortality, prevent development of heart failure, avoid the need for hospitalization and improve prognosis. ACE inhibitors may therefore have promising effects both on patients and on society. A challenge for the future must be early recognition and timely and adequate treatment of heart failure. Such a strategy might have great economic benefits as far as public health is concerned. However, the most rewarding efforts for the population will be to prevent the underlying causes of coronary heart failure as well as risk factors for heart failure. This review will study the magnitude of heart failure as a growing public health problem, the underlying causes, risk factors and treatment.
Similar articles
-
Heart failure--implications of the true size of the problem.J Intern Med. 1996 Apr;239(4):309-15. doi: 10.1046/j.1365-2796.1996.461800000.x. J Intern Med. 1996. PMID: 8774385 Review.
-
[Costs and benefits of heart failure treatment].Schweiz Med Wochenschr. 1999 Jan 30;129(4):131-7. Schweiz Med Wochenschr. 1999. PMID: 10087590 French.
-
Clinical and economic factors in the treatment of congestive heart failure.Pharmacoeconomics. 1995 Feb;7(2):119-27. doi: 10.2165/00019053-199507020-00004. Pharmacoeconomics. 1995. PMID: 10155299 Review.
-
[The treatment of heart decompensation using angiotensin converting enzyme inhibitors. Pharmaco-economic aspects].Rev Med Liege. 1998 May;53(5):255-8. Rev Med Liege. 1998. PMID: 9689878 French.
-
Angiotensin converting enzyme (ACE) inhibitors and heart failure. The consequences of underprescribing.Pharmacoeconomics. 1999 Jun;15(6):535-50. doi: 10.2165/00019053-199915060-00002. Pharmacoeconomics. 1999. PMID: 10538327 Review.
Cited by
-
Large animal models of congestive heart failure: a critical step in translating basic observations into clinical applications.J Nucl Cardiol. 2003 Jan-Feb;10(1):77-86. doi: 10.1067/mnc.2003.16. J Nucl Cardiol. 2003. PMID: 12569335 Review.
-
Practical implications of having a dedicated heart failure programme.Neth Heart J. 2005 Oct;13(10):343-347. Neth Heart J. 2005. PMID: 25696417 Free PMC article.
-
The Impact of Treatment with Beta-Blockers upon Mortality in Chronic Heart Failure Patients.Open Access Maced J Med Sci. 2016 Mar 15;4(1):94-7. doi: 10.3889/oamjms.2016.022. Epub 2016 Feb 8. Open Access Maced J Med Sci. 2016. PMID: 27275338 Free PMC article.
-
Empagliflozin in Patients With Heart Failure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Front Cardiovasc Med. 2021 Jun 22;8:683281. doi: 10.3389/fcvm.2021.683281. eCollection 2021. Front Cardiovasc Med. 2021. PMID: 34239906 Free PMC article.
-
Survival, exercise capacity, and left ventricular remodeling in a rat model of chronic mitral regurgitation: serial echocardiography and pressure-volume analysis.Korean Circ J. 2011 Oct;41(10):603-11. doi: 10.4070/kcj.2011.41.10.603. Epub 2011 Oct 31. Korean Circ J. 2011. PMID: 22125560 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous